ZHAOKE OPHTH-B (06622) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of 15.803 million yuan, representing a 68.25% decrease year-on-year, while net loss reached 117 million yuan, an increase of 53.85% compared to the same period last year.

According to the announcement, the increased loss was primarily attributed to the absence of one-time licensing income from a product licensing agreement that was recognized in the previous corresponding period. Additionally, research and development expenses rose due to the commencement of Phase I and Phase II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as the initiation of a new Phase III clinical trial for cyclosporine eye gel. These increases partially offset the continued reduction in administrative expenses during the reporting period.

The revenue decline was mainly due to changes in the company's sales strategy. The company has placed greater emphasis on expanding the distribution network for ophthalmic drugs while restructuring its sales team to concentrate on key sales regions. As a result, overall sales experienced a temporary and phased decline during the reporting period.